Osilodrostat, brand name Isturisa, is a medication for the treatment of adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease.
It is taken by mouth.
Pregnancy category AU: D
A Steroidogenesis inhibitor
The most common side effects are adrenal insufficiency, headache, vomiting, nausea, fatigue, and edema.
Hypocortisolism, QTc prolongation and elevations in adrenal hormone precursors and androgens may also occur in people taking osilodrostat.
Osilodrostat is an orally active, nonsteroidal corticosteroid biosynthesis inhibitor, for the treatment of Cushing’s syndrome and pituitary ACTH hypersecretion.
It acts as a potent and selective inhibitor of aldosterone synthase and at higher dosages of 11β-hydroxylase.
Osilodrostat’s safety and effectiveness for treating Cushing’s disease among adults was evaluated in a study of 137 adult subjects (about three-quarters women) with a mean age of 41 years.
The majority of subjects either had undergone pituitary surgery that did not cure Cushing’s disease or were not surgical candidates.
At the end of this 24-week period, about half of subjects had cortisol levels within normal limits.